EXACT SCIENCES INNOVATION MAKES THE MOVE TO THE OXFORD SCIENCE PARK
Incorporated in July 2019 by Oliver Waterhouse, an Entrepreneur in Residence at Oxford Science Enterprises, Base Genomics began as an innovative start-up working to set a new standard in DNA methylation with TAPS, a breakthrough technology that makes epigenetic analysis of DNA methylation more sensitive, accurate and cheaper than ever before. The TAPS technology was developed in Chunxiao Song’s laboratory at the University of Oxford’s Ludwig Institute for Cancer Research on the Old Road Campus.
At the end of 2020, Base Genomics was acquired by Exact Sciences, a US-based molecular diagnostics company, and became Exact Sciences Innovation (click here to read more about this).
Together, they are forming an Exact Sciences Centre of Innovation and are going through an exciting growth period. The centre's purpose is to change lives through earlier, smarter answers across the cancer journey. From earlier cancer detection to treatment guidance and monitoring, Exact Sciences Innovation is helping people get the answers they need to make more informed decisions across the cancer continuum.
We would like to thank the BioEscalator for its continued support throughout our journey – from the very start of Base Genomics, through our acquisition and fast growth as Exact Sciences, all of which have significantly driven us forward to having an impact on early detection and patient care. We loved being in the BioEscalator, and part of the community, and the support and flexibility from the BioEscalator team was invaluable.
- Hollie Coe, Director of Operations at Exact Sciences Innovation